

AD _____
(Leave blank)

Award Number:
W81XWH-11-1-0133

TITLE:
Characterizing SHP2 as a Novel Therapeutic Target in Breast Cancer

PRINCIPAL INVESTIGATOR:
Zachary Hartman

CONTRACTING ORGANIZATION:
West Virginia University
Morgantown, WV 26505

REPORT DATE:
February 2013

TYPE OF REPORT:
Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

- ☒ Approved for public release; distribution unlimited
- ☐ Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) February 2013		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 15 January 2012-14 January 2013	
4. TITLE AND SUBTITLE Characterizing SHP2 as a Novel Therapeutic Target in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0133	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Zachary Hartman				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) West Virginia University Morgantown, WV 26505				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research For Detrick, Maryland 21702-				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT - During this research period, molecular modeling and biochemical studies were conducted to assess roles of different acidic residues in the binding of the Src homology 2-containing protein tyrosine phosphatase (SHP2) to its substrates. A peptide derived from this substrate was shown to be a selective inhibitor of SHP2. SHP1 was used as a control, and the peptide did not act on this enzyme. Molecular modeling revealed key binding determinants at the atomic level present in SHP2 that could not be recapitulated in SHP1. These modeling observations were tested using mutation of the peptide. Indeed, when the peptide was mutated to abolish these interactions, inhibitory capacity was abolished entirely. Systematic mutation of the peptide in silico further demonstrated that the substrate needed to bind both of the positively-charged amino acid sidechains adjacent to the active site to facilitate the highest binding stability. Mutation of any of the acidic amino acids next to the phosphotyrosine on the substrate produced significant defects in binding as predicted by molecular docking. These findings are now being parlayed into study of the peptide-based.					
15. SUBJECT TERMS none provided					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	2
Body.....	3
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusion.....	6
References.....	7
Supporting Data.....	8

Introduction

The Src homology 2-containing protein tyrosine phosphatase (SHP2) is a positive regulator of cellular signaling and promotes breast cancer tumorigenesis. Because of this, it was hypothesized that SHP2 may be a useful therapeutic target in disease, since it acts as an integrator of numerous signaling pathways that are known to be dysregulated in cancer such as HER2. Previous cell biology work has demonstrated that SHP2 is required for maintenance of transformation. It has not been conclusively demonstrated that SHP2 would serve as an attractive therapeutic target. In addition, SHP2 inhibitors designed so far have failed to demonstrate selectivity over closely-related homologues such as SHP1 (1,2). This work was designed to first determine how SHP2 selectively binds its target substrates and then to apply this knowledge in the first-in-class demonstration of SHP2's viability as a therapeutic target in breast cancer.

Body

Over the course of the second year of study, research efforts have been focused on the statement of work tasks 3 and 4. They include the following overarching goals:

Task 3- Synthesize and characterize anti-SHP2 peptides derived from the Y1023-HER2 in vitro (Months 13-20)

Task 4- Molecular modeling of HER2 peptides (Months 13-20)

Both of these tasks serve a synergistic purpose. *In vitro* characterization of the substrate-derived peptide was used to confirm the predictions based on molecular modeling. Therefore, the results of this line of work will be discussed together.

The substrate-based peptide is a SHP2 inhibitor that does not target SHP1

Tyrosine 1023 of HER2 becomes phosphorylated in response to different stimuli, including EGF. SHP2 is known to act upon this site, dephosphorylating it. Dephosphorylation prevents the binding of the signaling inhibitor RasGAP, resulting in enhanced signaling (3). Since this is the only site on HER2 known to be engaged by SHP2, it was hypothesized that a peptide derived from the substrate sequence could act as a selective inhibitor. Thus, the peptide sequence DADEpYL was synthesized (pY representing phosphotyrosine) and tested against SHP2 and SHP1 activity. The Cheng-Prusoff equation was used to convert the IC_{50} into the inhibitory constant, K_i . The results are reported in Table 1. This peptide was found to have a K_i against SHP2 of 11.92 micromolar, whereas in SHP1 the inhibitory constant was found to be 630 micromolar. This large selectivity for SHP2 is unprecedented in the design of small molecule inhibitors. Therefore, the substrate-derived peptide was shown to be significantly more selective for SHP2 compared to its close homolog, SHP1.

Structural modeling predicts key interactions in the selective binding of the substrate-based peptide to SHP2.

A preliminary analysis of the primary sequence of the two enzymes revealed some differences in the region surrounding the active site (Figure 1A). Specifically, lysine 364 (K364) was found to be substituted with an arginine in SHP1, and arginine 362 (R362) of SHP2 was replaced by a lysine in SHP1. These residues have been previously suggested to play roles in selective binding of inhibitors(4). To understand how these differences may translate into conformational alteration of the active site, the crystal structures of SHP2 (2SHP.pdb) and SHP1 (1GWZ.pdb) were overlaid based on the catalytic region (Figure 1B). K364 in SHP2 was shown to be placed in the same location as an arginine in SHP1. These residues were conserved in terms of sidechain charge, but they differed significantly in terms of structure.

Since we found that the substrate-based peptide displayed selectivity for inhibition of SHP2 activity over, we wished to identify the intermolecular interactions that might be critical for binding to both enzymes. Since no crystal structure of SHP2 bound to this phosphopeptide is available, we attempted to elucidate interactions with molecular docking (5). The peptide was docked into the SH2 active site of 2SHP.pdb (with SH2 domains stripped from the crystal) using the genetic algorithm. At least 2000 runs were performed, and the most favorable conformation was selected (Figure 2). We ensured that the phosphotyrosine was situated inside the active site near the catalytic cysteine, an essential characteristic of binding in the PTP mechanism(6). Electrostatic interactions were computed in Autodock Tools. Strong ionic contacts were found between arginines and lysines to the acidic residues of the substrate peptide (Table 2), with the most prominent being the -2 position aspartate residue to K364 (-6.737 kcal/mol). Other strong predicted interactions included two contacts with the -4 position aspartate of the peptide to arginine 362 (-2.827 and -3.653 kcal/mol). The -2 aspartate also interacted with lysine 366 (-0.113 kcal/mol). Finally, the -1 glutamate residue of the peptide was predicted to hydrogen bond with Y279 of SHP2 (-2.903 kcal/mol). The total intermolecular interaction energy was found to be -14.3 kcal/mol with -8.50 kcal/mol originating from Van der Waals interactions and

hydrogen bonds and -5.80 kcal/mol provided by electrostatic interactions. Overall, the predicted K_i of the peptide was 9.72 μ M, which aligned reasonably well with the kinetics data we obtained.

Differences in selectivity for the peptide inhibitor were predicted by docking the same substrate-derived peptide into the SHP1 active site (Figure 3). Out of more than 2000 runs, the best docked structure predicted a K_i of 641 μ M, a rather dramatic loss of predicted inhibition compared to SHP2. Analysis of the structure revealed many electrostatic contacts between the peptide and the active site (Table 2). Arginine 358, which is analogous to lysine 364 of SHP2, was predicted to form an ionic bond with the -2 position aspartate of the peptide (-4.518 kcal/mol). Another electrostatic interaction was found between histidine 420 and the -1 glutamate of the peptide (-3.67 kcal/mol). The geometry of the predicted interactions was influenced by steric clashes. The orientation and size of arginine 358 appeared to create a pocket that required deformation of the peptide and atom contacts with the active site, resulting in a lowered overall binding energy.

In order to further corroborate the docking calculations of the wildtype peptide, docking was used to perform an *in silico* alanine scan. This was done by mutating the peptide's acidic amino acids into alanine and predicting the new binding conformation and affinity of the molecule. In this way, three new peptides were assessed, mutating at the -4, -2, and -1 positions. The results of this experiment are reported in Table 3.

The -1 mutant peptide, DADApYL, demonstrated a significantly poorer predicted inhibition constant when compared to the wildtype peptide. The constant predicted for this peptide was found to be 493.5 μ M. The predicted binding conformation of this peptide showed a tendency to form polar contacts with lysine 364 (Fig. 4). The peptide AADE predicted an even more pronounced loss of inhibition by the peptide, 608.21 μ M. Both lysine 364 and 366 were targeted for interaction by the peptide (Fig. 5). Finally, the DAAEpYL peptide was docked, yielding a predicted inhibition constant of 611.38 μ M. The most prominent sidechain interaction was found between lysine 364 and the -1 glutamate residue of the peptide (Fig. 6). This predicted inhibition is in reasonable agreement with the experimental results reported in Table 1 for this peptide.

The *in silico* alanine scan demonstrated two major findings about the binding of substrate peptide to SHP2. First, each of the acidic amino acids adjacent to the phosphotyrosine appears to play a critical role, since mutation of any of these engenders a dramatic loss of predicted binding capacity. Second, the peptides appear to show a preference for binding the lysine 364 residue to the exclusion of arginine 362 that was suggested to also play a deciding role in binding of the wildtype peptide. Since arginine 362 was not targeted, it would appear that binding to this residue is a key constituent of strong binding that leads to the low micromolar affinity of the wildtype peptide. Both the lysine 364 and arginine 362 form strong interactions with the peptide. This is particularly compelling, because, as noted in Figure 1, these two residues are swapped in SHP1, and the wildtype peptide cannot dock and form the same interactions as strongly with the new residues.

When combined, these data present strong evidence that the driving force of SHP2 selectivity is the interaction of molecules with both the lysine 364 and arginine 362 residues adjacent to the active site. This information will prove valuable in the future design of inhibitors in this field, since to date no drug has been designed that specifically targets the lysine 364 and arginine 362.

The substrate-based peptide is an inhibitor of SHP2-mediated cell signaling in cancer cells

The *in vitro* and *in silico* data of the peptide were compelling evidence for the substrate-derived peptide's ability to inhibit SHP2 activity in a selective manner. Next, it was determined what kind of effect this peptide might have on cells. As laid out in task 6 (Test the efficacy of peptide inhibitors against SHP2-mediated cell signaling and transformation), I tested the hypothesis that the peptide could act to inhibit SHP2 in cells, conferring an effect on signaling similar to that seen when SHP2 expression is inhibited using short-hairpin RNA. Specifically, suppression of SHP2 inhibits the ability for EGF to stimulate the mitogen-activated protein kinase (MAPK) pathway, which is read as a drop in phosphorylated ERK protein(3).

First, the problem of cell permeability needed to be overcome. The phosphobenzene moiety of the peptide confers significant negative charge to the peptide, making it unlikely to enter the cell spontaneously. To solve this problem, the peptide sequence was altered to include the cell-penetrating sequence from the HIV TAT1 protein, which has been shown to facilitate delivery of different types of cargo into cells (7). The peptide was also tagged with fluorescein isothiocyanate (FITC) to determine if it was being successfully internalized into cells. BT474 has been tested so far with this peptide. These HER2-positive cancer cells are ideal to model EGF response and dependence on SHP2. First, they were grown to confluence. Once they reached this stage, the cells were serum-starved overnight. The following morning, the peptide was incubated with the cells for one hour before EGF was added to a concentration of 100 ng/mL. The FITC channel of an Olympus X78 microscope was used to verify internalization of the FITC tag (Figure 7). It was noted that the phosphorylated form of the peptide was able to localize to the membrane in response to EGF, which suggests that it may be acting upon SHP2 in this region. SHP2 is recruited to the membrane independently of HER2 through the Grb2-associated protein 2, an adapter molecule that is recruited to the membrane following EGF stimulation. The non-phosphorylated peptide did not show this same localization, but it was significantly internalized thanks to the TAT1 tag.

Under the same conditions, EGF-mediated activation of the MAPK signaling pathway was tested in the presence of the phosphorylated and non-phosphorylated peptides (Figure 8). The non-phosphorylated peptide showed no change in the signaling intensity or duration, while the phosphorylated form strongly inhibited both the initial spike and the duration of phosphorylated ERK signal. These results strongly suggest that the substrate-derived peptide inhibitor can suppress SHP2 activity in cells in addition to *in vitro* experiments.

In the coming months, this peptide will be tested in other cell lines and against other phenotypes related to cancer. These include migration and anchorage-independent growth.

Key Research Accomplishments

- A peptide derived from the known SHP2 substrate HER2 is a selective inhibitor of enzymatic activity *in vitro*.
- Association with positively charged amino acids lysine 364 and arginine 362 is critical for binding SHP2.
- The same binding interactions for SHP2 cannot be recapitulated in SHP1 despite similarities in sequence. The structure of the active site of SHP1 does not allow for the same interactions to occur.
- The substrate-derived peptide, once fused to a cell-penetrating sequence, can act as an inhibitor of SHP2-mediated signaling in HER2-positive breast cancer cells.

Reportable Outcomes

- Poster presentation at the 2012 WVU Van Lier Research Day
- Imminent publication of a paper in Molecular Cancer Research regarding the role of SHP2 in metastasis and cell migration (final revision), helping to further characterize SHP2 as a therapeutic target in breast cancer
- Final stages of paper submission to the Journal of Biological Chemistry regarding the determination of SHP2 selectivity

Conclusions

The work gathered into this report represents a significant milestone in the characterization of SHP2. To date, many labs have attempted to design or screen for inhibitors against this enzyme with little success (2,4,8-10). This work has yielded some very interesting observations regarding what can make for a selective inhibitor, but no group has yet reached satisfactory levels. What the results presented here show is that selectivity can be achieved for SHP2 over SHP1 (the most challenging enzyme pair to inhibit selectively due to sequence homology), and, more importantly, it is the association of negatively-charged functional groups with the positively-charged amino acids of SHP2 adjacent to the active site that mediate the selectivity. Specifically, interactions with both arginine 362 and lysine 364 near the active site appear to be crucial for binding to SHP2, since mutations in the peptide that abolish one of these interactions remove the inhibitory capacity. These same interactions cannot be formed by the peptide in SHP1 as predicted by molecular docking, suggesting a strategy for selective inhibition by a peptidomimetic.

References

1. Chen, L., Sung, S. S., Yip, M. L., Lawrence, H. R., Ren, Y., Guida, W. C., Sebt, S. M., Lawrence, N. J., and Wu, J. (2006) *Molecular pharmacology* **70**, 562-562
2. Barr, A. J. *Future medicinal chemistry* **2**, 1563-1576
3. Zhou, X., and Agazie, Y. M. (2009) *The Journal of biological chemistry* **284**, 12226-12234
4. Hellmuth, K., Grosskopf, S., Lum, C. T., Wurtele, M., Roder, N., von Kries, J. P., Rosario, M., Rademann, J., and Birchmeier, W. (2008) *Proceedings of the National Academy of Sciences of the United States of America* **105**, 7275-7280
5. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) *Journal of Computational Chemistry* **19**, 1639-1662
6. Mohi, M. G., and Neel, B. G. (2007) *Current opinion in genetics & development* **17**, 23-30
7. Järver, P., and Langel, U. (2004) *Drug discovery today* **9**, 395-402
8. Yu, Z.-H., Chen, L., Wu, L., Liu, S., Wang, L., and Zhang, Z.-Y. *Bioorganic & medicinal chemistry letters* **21**, 4238-4242
9. Zhang, X., He, Y., Liu, S., Yu, Z., Jiang, Z. X., Yang, Z., Dong, Y., Nabinger, S. C., Wu, L., Gunawan, A. M., and others. (2010) *Journal of medicinal chemistry* **53**, 2482-2493
10. Yu, Z.-H., Chen, L., Wu, L., Liu, S., Wang, L., and Zhang, Z.-Y. (2011) *Bioorganic & medicinal chemistry letters* **21**, 4238-4242

Supporting Data

Table 1. Inhibition of SHP1 and SHP2 by substrate-derived peptides.

Peptide	Predicted Ki (μM)	Experimental Ki (μM)
DADEpYL		
SHP1	641	630.0
SHP2	9.72	11.97
DAAEpYL		
SHP2	611.38	856.8

Table 2. Predicted electrostatic energies of interactions between the peptide and SHP1/SHP2^a

Peptide to SHP2	Energy	Peptide to SHP1	Energy
-1 Glu to Y279	-2.903	-1 Glu to H420	-3.67
-2 Asp to K364	-6.737	-1 Asp to K356	-0.301
-2 Asp to K364	-0.113	-2 Asp to R359	-4.518
-4 Asp to R362	-2.827	-2 Asp to R359	-0.26
-4 Asp to R362	-3.653	-4 Asp to K356	-0.007

^a Energy in kcal/mol

Table 3. *In silico* alanine scan of the peptide, bound to SHP2

Peptide	Predicted Ki (μM)
DADApYL	493.5
DAAEpYL	611.38
AADEpYL	608.21




Figure 3. Computational docking of the substrate-derived peptide into the SHP1 active site
a) Substrate-derived peptide was docked into the SHP1 active site using Autodock4, and the binding mode is presented with SHP1 residues represented using the CPK model. b) Interactions between the peptide and the SHP1 active sites. Peptide residues are labeled based on their sequence position relative to the phosphotyrosine. Polar contacts are indicated by green dots.




Figure 4. Predicted binding conformation of the DADApYL peptide to SHP2. Predicted hydrogen bonds are represented by green spheres.




Figure 5. Predicted binding conformation of the DAAEpYL peptide to SHP2. Predicted hydrogen bonds are represented by green spheres.




Figure 6. Predicted binding conformation of the AADEpYL peptide to SHP2. Predicted hydrogen bonds are represented by green spheres.




Figure 7. Successful internalization and pY-dependent membrane localization of the FITC-tagged substrate-derived peptide. BT474 cells were grown to confluence before serum-starving overnight. Then, EGF (100 ng/mL) was added in the presence of either phosphorylated peptide or non-phosphorylated peptide. Penetration into the cell was facilitated by incorporating the cell-penetrating peptide sequence from HIV-TAT1.




Figure 8. A phosphorylated substrate-based peptide acts as an inhibitor of signaling *in vitro*. BT474 cells were grown to confluence before serum-starving overnight. Then, EGF (100 ng/mL) was added for the indicated times in the presence of either phosphorylated peptide or non-phosphorylated peptide. Penetration into the cell was facilitated by incorporating the cell-penetrating peptide sequence from HIV-TAT1.